摘要
目的:观察延长使用低分子肝素治疗高原非ST段抬高型急性冠脉综合征(NSTE-ACS)患者的疗效及安全性。方法:将85例NSTE-ACS患者随机分为常规治疗组(n=42)和延长治疗组(n=43),常规治疗组采用低分子肝素(依诺肝素)皮下注射治疗5~7 d,延长治疗组治疗10~14 d,其余基础治疗相同。观察30 d内心血管事件、出血事件和血小板减少的发生率。结果:常规治疗组30 d内心血管事件的发生率为19%,延长治疗组为5%,两组间有显著差异(P<0.05);常规治疗组30 d内出血事件的发生率为5%,延长治疗组为5%,两组间无显著差异;两组患者中均未观察到血小板减少和APTT延长的发生。结论:延长使用(10~14 d)低分子肝素治疗高原NSTE-ACS可显著降低30 d内心血管事件的发生率,且不增加出血风险和血小板减少事件的发生率。
AIM: To observe the effectiveness and safety of delayed therapy with low molecular weight heparin(LMWH) in patients with non-ST segment elevation acute coronary syndrome(NSTE-ACS) at high altitude.METHODS: Eighty-five patients with NSTE-ACS were randomized into conventional therapy group(n=42) and delayed therapy group(n=43).Patients in conventional group received LMWH therapy for 5 to 7 days,whereas patients in delayed group received LMWH for 10-14 days.The basic therapy was similar in both groups.The incidences of cardiovascular events,hemorrhage and platelet reduction within 30 days were recorded.RESULTS: The incidence of cardiovascular events within 30 days in conventional group was significantly higher than that in delayed group(19.0% vs.4.7%,P0.05).The incidence of hemorrhage was similar between groups(4.8% vs.4.7%,P0.05).No reduction in platelet count and no increase in activated partial thromboplastin time(aPTT) were observed.CONCLUSION: The strategy of delayed therapy with LMWH will significantly decrease the incidence of cardiovascular events in patients with NSTE-ACS at high altitude within 30 days and will not significantly increase hemorrhage risks.
出处
《心脏杂志》
CAS
2011年第6期767-769,共3页
Chinese Heart Journal
基金
成都军区医学科研计划课题(MB09016)
关键词
高原
低分子肝素
急性冠脉综合征
high altitude
low molecular weight heparin
acute coronary syndrome